Effects of iNO on Invasively Derived Pulmonary Vascular Parameters in Patients With Pulmonary Arterial Hypertension

Trial Profile

Effects of iNO on Invasively Derived Pulmonary Vascular Parameters in Patients With Pulmonary Arterial Hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2017

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 May 2017 New trial record
    • 07 Apr 2017 According to a Bellerophon Therapeutics Media Release, results presented at 37th Annual Meeting for the International Society for Heart and Lung Transplantation (ISHLT, 2017).
    • 07 Apr 2017 Results published in a Bellerophon Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top